Acted on behalf of Daiken Biomedical CO., LTD., an important subsidiary, to clarify relevant media reports

 Acted on behalf of Daiken Biomedical CO., LTD.,
an important subsidiary, to clarify relevant media reports

1.Date of occurrence of the event:2024/09/27
2.Company name:Daiken Biomedical CO., LTD.
3.Relationship to the Company (please enter "head office" or
  "subsidiaries"):Subsidiary
4.Reciprocal shareholding ratios:Not Applicable
5.Name of the reporting media:Public Television, Yahoo, and other news reports
6.Content of the report:
 A red yeast product from Japan's Kobayashi Pharmaceutical has led to
  allegations of kidney damage by consumers in Taiwan who used products made
  from this raw material. Today (26th), the Taiwan Consumer Protection
  Association officially filed a class action lawsuit on behalf of 55
  Taiwanese individuals. The defendants include Daiken Biomedical, the
  subsidiary of our company, and five other importers, with the lawsuit
  seeking approximately  NT$170 million in damages.
7.Cause of occurrence:
 The subsidiary, Daiken Biomedical CO., LTD., previously imported the
  red yeast raw material from Kobayashi Pharmaceutical to produce CoQ10
  red yeast products. Due to the aforementioned incident with Kobayashi red
  yeast, consumer disputes and a class action lawsuit have been initiated.
8.Countermeasures:
 (1) The subsidiary, Daiken Biomedical CO., LTD., has not yet received
     the indictment mentioned in the news. In the past, there has been no
     situation where the company failed to respond to consumer complaints.
     Daiken will further clarify the details of the report and, upon
     receiving the indictment, will consult with the legal department to
     draft a defense.
 (2) Both our company and the subsidiary have always operated steadily,
     and this case does not pose any potential impact on our company's
     financial status. Investors are advised to refer to the company's
     announcements on the Market Observation Post System for accurate
     financial and business information.
9.Any other matters that need to be specified:None.